June 10, 2005 -- A late-day surge did much to trim losses today, a quiet session that was typical of a summer Friday. Officially, the day was mixed, with some indexes higher and others, especially Nasdaq, staying negative. Biotech did well to lose just a few points. At the close, the Centient Biotech 200 was off by 5 points at 3334.53, a loss of .14%. Lilly set aside $690 million to settle Zyprexa lawsuits, the NY Times reported Johnson & Johnson covered up heart attack problems with Propulsid for years before finally taking the drug off the market, Immunomedics said its drug proved effective against Sjogren’s syndrome, Crucell discovered an antibody to West Nile virus, Insmed faces a longer wait for FDA approval on its growth hormone, Alteon halted tests on its high blood pressure medication, and Enzo in-licensed a drug candidate for uveitis. More details...
